MP
TOVX icon

MSD Partners’s Theriva Biologics TOVX Stock Holding History

MSD Partners’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,316
Closed -$37.7K – 17
2024
Q3 		$37.7K Buy
27,316
+3,380
+14% +$16.5K 0.02% 17
2024
Q2 		$141K Buy
+23,936
New +$209K 0.01% 16
2022
Q3 		– Sell
-466
Closed -$25K – 89
2022
Q2 		$25K Hold
466
– – ﹤0.01% 88
2022
Q1 		$33K Sell
466
-931
-67% -$63.4K ﹤0.01% 93
2021
Q4 		$96K Buy
1,397
+931
+200% +$87.8K ﹤0.01% 116
2021
Q3 		$53K Hold
466
– – ﹤0.01% 107
2021
Q2 		$70K Sell
466
-3,377
-88% -$484K ﹤0.01% 106
2021
Q1 		$655K Buy
+3,843
New +$759K 0.02% 63
2018
Q3 		– Sell
-471
Closed -$984K – 46
2018
Q2 		$984K Hold
471
– – 0.04% 36
2018
Q1 		$1.31M Hold
471
– – 0.07% 28
2017
Q4 		$2.09M Hold
471
– – 0.11% 17
2017
Q3 		$3.84M Hold
471
– – 0.11% 28
2017
Q2 		$2.33M Hold
471
– – 0.14% 31
2017
Q1 		$2.6M Hold
471
– – 0.13% 28
2016
Q4 		$3.14M Buy
471
+115
+32% +$1.18M 0.16% 26
2016
Q3 		$5.36M Hold
356
– – 0.43% 25
2016
Q2 		$5.61M Sell
356
-125
-26% -$2.35M 0.37% 43
2016
Q1 		$9.93M Hold
481
– – 0.52% 36
2015
Q4 		$9.64M Hold
481
– – 0.41% 37
2015
Q3 		$9.55M Buy
481
+71
+17% +$1.75M 0.31% 44
2015
Q2 		$10.2M Hold
410
– – 0.21% 52
2015
Q1 		$7.85M Hold
410
– – 0.19% 59
2014
Q4 		$5.23M Buy
410
+104
+34% +$1.4M 0.12% 50
2014
Q3 		$4.76M Hold
306
– – 0.14% 49
2014
Q2 		$4.6M Hold
306
– – 0.12% 51
2014
Q1 		$6.88M Hold
306
– – 0.26% 47
2013
Q4 		$4.09M Buy
306
+66
+28% +$833K 0.17% 57
2013
Q3 		$3.53M Hold
240
– – 0.13% 53
2013
Q2 		$3.61M Buy
+240
New +$3.28M 0.2% 41

Other funds holding TOVX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IHWM
Iron Horse Wealth Management Johston, Iowa $339M AUM 10.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

MSD Partners's TOVX Position: Q4 2024 in Review

MSD Partners sold out of Theriva Biologics (TOVX) in Q4 2024, closing a stake of 27,316 shares — an estimated $37.7K sold.

MSD Partners first reported a position in TOVX in Q2 2013 and held it in 29 quarters. The position peaked at $10.2M in Q2 2015. 10 funds tracked by Wall St. Rank hold TOVX as of Q4 2024.

  • MSD Partners reported no remaining Theriva Biologics position as of Q4 2024 after selling out during the quarter.
  • MSD Partners sold 27,316 Theriva Biologics shares in Q4 2024, an estimated $37.7K.
  • MSD Partners first reported a position in Theriva Biologics in Q2 2013 and held it in 29 quarters.
  • MSD Partners's Theriva Biologics position peaked at $10.2M in Q2 2015.
  • 10 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2024.

Based on MSD Partners's 13F filing for Q4 2024, filed 14 Feb 2025.